• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.

作者信息

Roberts Holly J, Ji Sunjong, Picca Alberto, Sanson Marc, Garcia Mekka, Snuderl Matija, Schüller Ulrich, Picart Thiébaud, Ducray François, Green Adam L, Nakano Yoshiko, Sturm Dominik, Abdullaev Zied, Aldape Kenneth, Dang Derek, Kumar-Sinha Chandan, Wu Yi-Mi, Robinson Dan, Vo Josh N, Chinnaiyan Arul M, Cartaxo Rodrigo, Upadhyaya Santhosh A, Mody Rajen, Chiang Jason, Baker Suzanne, Solomon David, Venneti Sriram, Pratt Drew, Waszak Sebastian M, Koschmann Carl

机构信息

Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.

Department of Neurology-2, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

出版信息

Acta Neuropathol. 2023 Dec;146(6):849-852. doi: 10.1007/s00401-023-02640-7. Epub 2023 Oct 18.

DOI:10.1007/s00401-023-02640-7
PMID:37851269
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10627895/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4261/10627895/c2792ea14e84/401_2023_2640_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4261/10627895/c2792ea14e84/401_2023_2640_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4261/10627895/c2792ea14e84/401_2023_2640_Fig1_HTML.jpg

相似文献

1
Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.H3K27M突变型弥漫性中线胶质瘤长期存活者的临床、基因组和表观基因组分析揭示了一组具有MAPK通路改变的独特肿瘤。
Acta Neuropathol. 2023 Dec;146(6):849-852. doi: 10.1007/s00401-023-02640-7. Epub 2023 Oct 18.
2
Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.弥漫性中线胶质瘤，H3K27M 突变型和间变性室管膜瘤的单细胞 RNA 测序。
BMC Neurol. 2024 Feb 21;24(1):74. doi: 10.1186/s12883-024-03558-7.
3
Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.具有非中线位置的 H3K27M 突变弥漫性神经胶质瘤的特征。
J Neurooncol. 2024 Sep;169(2):391-398. doi: 10.1007/s11060-024-04733-z. Epub 2024 Jun 27.
4
A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.390 例 H3F3A 突变型小儿和成人弥漫性高级别神经胶质瘤，CNS WHO 分级 4 的全面基因组研究
Acta Neuropathol. 2023 Sep;146(3):515-525. doi: 10.1007/s00401-023-02609-6. Epub 2023 Jul 31.
5
Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?弥漫性半球胶质瘤伴 H3 p.K28M（K27M）突变：弥漫性中线胶质瘤 H3 K27M 改变的非中线部位不常见表现？
J Neuropathol Exp Neurol. 2024 Apr 19;83(5):357-364. doi: 10.1093/jnen/nlae018.
6
Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.靶向检测遗传改变揭示了 H3K27M 和 MAPK 通路异常在儿童丘脑胶质瘤中的预后影响。
Acta Neuropathol Commun. 2016 Aug 31;4(1):93. doi: 10.1186/s40478-016-0353-0.
7
Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.H3K27M 突变在大脑半球“非中线”高级别胶质瘤中的意义。
World Neurosurg. 2019 Nov;131:174-176. doi: 10.1016/j.wneu.2019.08.024. Epub 2019 Aug 12.
8
Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.弥漫性中线胶质瘤 H3K27M 突变型的预后标志物的鉴定。
Brain Pathol. 2020 Jan;30(1):179-190. doi: 10.1111/bpa.12768. Epub 2019 Aug 14.
9
Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.弥漫性中线胶质瘤-H3K27M突变型。一种具有明确且特异性免疫组化标志物的新实体。
Indian J Pathol Microbiol. 2021 Apr-Jun;64(2):351-353. doi: 10.4103/IJPM.IJPM_287_20.
10
Four methods to analyze H3K27M mutation in diffuse midline gliomas.分析弥漫性中线胶质瘤 H3K27M 突变的四种方法。
Pathol Res Pract. 2020 Sep;216(9):153065. doi: 10.1016/j.prp.2020.153065. Epub 2020 Jun 18.

引用本文的文献

1
Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.小儿型弥漫性胶质瘤中具有启发性的放射基因组特征：分子、临床和影像相关性洞察。第一部分：高级别组。
Radiol Med. 2025 Aug 25. doi: 10.1007/s11547-025-02078-9.
2
Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.建立一个适用于癌症药理学的儿童高级别胶质瘤和室管膜瘤的生物样本库。
Neuro Oncol. 2025 Jun 21;27(5):1325-1340. doi: 10.1093/neuonc/noaf007.
3
The role of brainstem biopsy and targeted therapies in pediatric diffuse midline glioma/diffuse intrinsic pontine glioma.

本文引用的文献

1
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
2
Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations.在83例伴有H3F3A K27M突变的弥漫性中线胶质瘤系列病例中，FGFR1基因内的突变与较好的预后相关。
Acta Neuropathol. 2021 Feb;141(2):323-325. doi: 10.1007/s00401-020-02259-y. Epub 2021 Jan 12.
3
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.
脑干活检及靶向治疗在儿童弥漫性中线胶质瘤/弥漫性脑桥内在型胶质瘤中的作用
Front Oncol. 2024 Dec 23;14:1504440. doi: 10.3389/fonc.2024.1504440. eCollection 2024.
4
Intravenous and intracranial GD2-CAR T cells for H3K27M diffuse midline gliomas.用于H3K27M弥漫性中线胶质瘤的静脉内和颅内GD2嵌合抗原受体T细胞
Nature. 2025 Jan;637(8046):708-715. doi: 10.1038/s41586-024-08171-9. Epub 2024 Nov 13.
5
H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications.中枢神经系统肿瘤中H3K27me3缺失：诊断、预后及治疗意义
Cancers (Basel). 2024 Oct 11;16(20):3451. doi: 10.3390/cancers16203451.
6
BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country.BRAF/MEK抑制剂在儿童胶质瘤中的应用；来自资源有限国家的真实世界经验。
Front Oncol. 2024 Sep 27;14:1417484. doi: 10.3389/fonc.2024.1417484. eCollection 2024.
7
Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance.整合分析揭示 H3 K27M 突变型弥漫性中线神经胶质瘤的两种具有预后意义的分子和临床明显不同亚型。
Acta Neuropathol. 2024 Sep 10;148(1):40. doi: 10.1007/s00401-024-02800-3.
8
The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors.放疗、化疗及靶向治疗在成人脊髓髓内肿瘤中的作用
Cancers (Basel). 2024 Aug 6;16(16):2781. doi: 10.3390/cancers16162781.
9
Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.脊髓星形细胞瘤的分子病理学、诊断和治疗进展。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241262483. doi: 10.1177/15330338241262483.
10
H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.脑桥 H3K27 改变弥漫性中线胶质瘤：从分子机制到靶向干预。
Cells. 2024 Jun 28;13(13):1122. doi: 10.3390/cells13131122.
对 1000 例小儿低级别胶质瘤的综合分子与临床分析。
Cancer Cell. 2020 Apr 13;37(4):569-583.e5. doi: 10.1016/j.ccell.2020.03.011.
4
DNA methylation-based classification of central nervous system tumours.基于 DNA 甲基化的中枢神经系统肿瘤分类。
Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.
5
Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas.局限性/非弥漫性组织学在H3K27M突变型胶质瘤中预示着更好的预后。
Acta Neuropathol. 2018 Feb;135(2):299-301. doi: 10.1007/s00401-018-1805-3. Epub 2018 Jan 4.
6
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.K27M 突变的组蛋白 H3.3 定义了具有临床和生物学特征的不同亚组的儿童弥漫性内在脑桥胶质瘤。
Acta Neuropathol. 2012 Sep;124(3):439-47. doi: 10.1007/s00401-012-0998-0. Epub 2012 Jun 3.